Non-Therapeutic Partnerships

Applications of ZFNs are broad-based and we have monetized our ZFN-mediated genome editing platform by executing channel collaborations in fields outside human therapeutics.

Sigma-Aldrich Corporation

Sigma-Aldrich Corporation

We have a license agreement with the world-wide research reagent company, Sigma-Aldrich Corp. (Sigma). Sigma has the exclusive right to develop and market high value laboratory research reagents based on Sangamo’s ZFP technology as well as ZFP-modified cell lines for commercial production of protein pharmaceuticals and ZFP-engineered transgenic animals. Sigma is marketing ZFN-mediated genome editing tools under the trademark CompoZr®, and is selling ZFN-engineered transgenic animals through SAGE™ Labs.

Dow AgroSciences LLC

Dow AgroSciences LLC

We have a license agreement with Dow AgroSciences (DAS), a wholly owned subsidiary of Dow Chemical Corporation. Under the agreement, DAS has the exclusive right to use our ZFP technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. DAS is marketing ZFN-mediated genome edited plant products under the trademark EXZACT™ Precision Technology. We have retained rights to use plants or plant-derived products to deliver ZFP TFs or ZFN products into human or animals for diagnostic, therapeutic, or prophylactic purposes.